The potentialities of Streptomyces lividans 1326 as new live vaccine vehicle strategy have been evaluated. Immunization of mice with the Streptomyces mycelium induced high levels of specific antibodies against proteins released in the culture supernatant of the analyzed strain. Splenocytes from the Streptomyces-immunized animals were able to secrete high levels of IFN-(2103.9 pg/mL) and to proliferate in vitro on stimulation with proteins released by Streptomyces. The analysis of cross-reactivity against M. tuberculosis secreted proteins showed that the immunization of mice with Streptomyces led to a comparable level of cross-reacting antibodies as in the BCG immunized mice. Similarly sera antibodies from Streptomyces immunized group recognized whole BCG cells to the same degree as antibodies raised against BCG reacted with Streptomyces mycelium, indicating that these two actinobacteria cross-react immunologically.
INTRODUCTION
The current vaccine against tuberculosis (TB), bacille Calmette-Guérin (BCG), is a live vaccine derived from an attenuated strain of Mycobacterium bovis. BCG protects against severe childhood forms of the disease, but fails to protect against adult pulmonary TB in countries where it is endemic. Also, there are 8 million people worldwide developing active TB annually causing 3 million deaths [1] . It is estimated that one-third of the world's population is latently infected with Mycobacterium tuberculosis. These people become a natural reservoir for the propagation of the bacilli, and cases of active tuberculosis can occur during endogenous reactivation of such a latent infection or following exogenous reinfection [2, 3] .
More than one vaccine is needed: one to be delivered to infants who basically have a naive immune system against M. tuberculosis and the nontuberculous mycobacteria, another to treat previously infected people and a third one for therapy of people who have developed the active disease [4] .
*Address correspondence to this author at the Institute of Pharmacy and Food, University of Havana, Cuba; E-mail: val@infomed.sld.cu As a result of the needs, vaccine candidates against TB have been generated in the last 10 years which were tested in different laboratory assays [5] , experimental animal models [6, 7] , and clinical trials in human populations [8] .
Recently, a new microorganism has been suggested to be a suitable candidate for developing TB vaccines, namely Streptomyces lividans. This bacterium belongs to one of the major branches of the Gram-positive bacteria: the high G-C organisms referred to as actinomycetes [9] . Mycobacterium tuberculosis belongs to a suprageneric group inside the actinomycetes genera, the Mycobacteriaceae family, which is phylogenetically closely related to the Streptomycetaceae family [10, 11] . Streptomycetes are ubiquitous having soils for natural habitat. Furthermore Streptomyces strains have been well-known for many years as sources of natural antibiotics and S. lividans, a GRAS (generally recognized as safe) microorganism, has been successfully used for the heterologous production of several proteins of eukaryotic and bacterial origin including antigens from M. tuberculosis [12] [13] [14] [15] . Among human diseases caused by actinomycetes there is only one known member of the genus Streptomyces: S. somaliensis. Taking into account all these features of S. lividans it is important to study the immune response toward this bacterium in an animal model prior to be considering it as a tool for developing TB vaccines.
In this paper we have assessed the immunogenicity of S. lividans strain 1326 in comparison with BCG in BALB/c mice, in order to determine if a live vaccine candidate would be capable of inducing appropriate humoral and cellular immune responses.
MATERIALS AND METHODS

Bacterial Strains
The commercial BCG vaccine strain from Denmark (batch: Copenhagen 1331) was used as a positive control of immunization with a bacterial strain.
S. lividans strain 1326 was obtained from the Streptomyces culture collection of the Jones Innes Centre, Norwich, England (kindly provided by the Professor D.A. Hopwood). This is a commonly used host strain that has no or weak restriction against heterologous DNA [16] and a low level of endogenous protease activity [17] .
Preparation of the Immunogen of Streptomyces Cells
S. lividans 1326 was grown in an orbital shaker at 28 o C for 48 h in 100 ml modified BTSB medium [18] : 10% sucrose, 1% yeast extract, 0.5% NaCl, 0.3% soy meal, 1.7% tryptone and 0.25% K 2 HPO 4 , pH 7.2. Streptomyces mycelium was harvested by centrifugation (3500 rpm, 4 o C), washed with and resuspended in PBS. Aliquots (1 ml) were lyophilized and kept at 4°C until use. Three lyophilized bulbs were resuspended and plated on MRYE medium [19] to determine the total number of CFU per bulb from each lot preparation. Briefly: lyophilized bulbs were resuspended in 1 mL of PBS and 100 L of dilutions (from 10 5 to 10 2 ) were plated to count the number of CFU. The following formula was used to determine the number of CFU in each bulb, No. CFU/bulb = No. counted CFU/plate x Dilution factor x 10.
The proteins of the resulting culture supernatant were desalted using PD-10 columns (GE Healthcare, supplied by BDC, Belgium) and PBS as exchange buffer. Then proteins were filtered (0.22 μm, Millipore) and kept at -20 o C until use. The total protein content was determined using the Bradford method [20] .
Preparation of Proteins Secreted by M. tuberculosis and M. bovis Strains
The secreted proteins from M. tuberculosis H37Rv and M. bovis 1331 were obtained starting from a short-term culture filtrate (ST-CF) as previously described [21] . Briefly, the strains (8 x 10 6 CFU/ml) were grown in a modified media of Sauton without Tween 80 in orbital shaker to 37 o C for 4 to 7 days. The culture supernatants were sterile filtered and proteins from them were obtained in the same way as Streptomyces secreted proteins.
Animals
Female BALB/c mice (18-20 g ) were purchased from the National Center for Laboratory Animal Production (CEN-PALAB, Havana, Cuba). They were housed in Macrolon cages (Panlab, Barcelona, Spain), in a standard bio-clean animal room, and kept under a 12-h light-dark cycle at 22-24°C. The animals had free access to food and tap water, and were allowed to acclimatize for one week before the experiments. All experiments were carried out in accordance with the ethical guidelines for investigations with laboratory animals and were approved by the Ethical Committee for Animal Experimentation of the Center of Biomolecular Chemistry.
Immunization Scheme
Three experimental groups (8 mice each) were immunized in the intraperitoneal region following the schedule shown in Table 1 . Mice were bled by the retro-orbital artery with a sterilized Pasteur micropipette. For the immunization with Streptomyces cells: the mycelium was resuspended in PBS to a concentration of 5x10 6 CFU per mL and 0.2 ml of this Streptomyces cell suspension was given to each animal (the volume of PBS for resuspending the lyophilized bulbs was calculated by the formula: V (mL)= No. CFU/bulb /5x10 6 CFU/mL). The BCG vaccine strain was resuspended in its medium to a concentration of 10 7 CFU per mL and 0.1 mL of this BCG suspension was given to each animal. This immunization experiment was done twice, data from one are presented.
Enzyme-Linked Immunosorbent Assay (ELISA) and Western Blot Assay
Antibody levels against proteins secreted by Streptomyces, BCG and M. tuberculosis, and antibodies levels against whole Streptomyces cells and whole BCG cells were measured by indirect ELISA (described in [18] ). The nature of the antigens identified by serum antibodies of immunized animals was identified by Western blot analysis. Briefly: the antigens were separated by electrophoresis of proteins on 12.5% SDS-polyacrylamide gels. Separated proteins were visualized by Coomassie brilliant blue staining or transferred to a Hybond™-C extra membrane (GE Healthcare, supplied by BDC, Belgium) by using a semidry transfer cell (Biometra, Göttingen, Germany) according to the manufacturer's recommendations. Membranes were incubated with a pool of mice sera from the analyzed group diluted 1:10. Antimouse IgG horseradish peroxidase conjugated (Promega, Catalys AG, Switzerland) diluted 1:5000 was used as secondary antibody. Immunoreactive bands were visualized by brief exposure to 3,3-diaminobenzidine as substrate. Images were taken by the Bioimage System GENE GENIUS (SynGene, Cambridge, UK).
Antigen-Specific Lymphocyte Proliferative Response
Lymphocytes were obtained from the spleens of killed mice and were purified by Ficoll density gradient centrifugation (Histopaque SIGMA, St Louis, MO, USA). The cellular suspension was adjusted to a working dilution of 2 10 6 cells/mL. Lymphocytes were cultured in U-bottom 96-well microtiter plates (Corning, Life Science, US) in complete RPMI medium at 37°C under 5% CO 2 and challenged with the corresponding antigen at 10 g/mL (a control without antigen stimulation was included for each group). Spleens from 3 mice in each group were pooled. In order to determine cytokine production leukocyte culture supernatants were collected after 96 h and stored at -20 ºC until use. The lymphocyte proliferation was assessed by the colorimetric assay based on the mitochondrial enzymatic reduction of the reagent MTT (3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide, SIGMA, St Louis, MO, USA) to purple formazan in living cells [22] . Briefly, 15 μL of MTT (final concentration 0.5 mg/mL) were added to the wells and the cells were incubated during 4 hours. At the end, DMSO was added to dissolve the insoluble purple formazan product into a colored solution. The absorbance of the colored solution was measured at 540 nm. The experiment was done twice in duplicate and data are expressed as mean absorbance of the groups and the standard error of the mean.
Determination of IFN-and IL-10 Produced by Challenged Leukocytes
Cytokine determination was done using double antibody system ELISA kits (MabTech, Sweden) following manufacturer's recommendations. Positive stimulation was considered when the cytokine level was fivefold higher than in the non-stimulated wells of the corresponding group.
Statistical Analysis
Statistical differences between groups were determined by a Kruskal-Wallis test and the Dunn's multiple comparison post test. The analyses were conducted using the software GraphPad Prism version 4.00 for Windows (GraphPad Software, San Diego California, USA). The first aim for evaluating a live candidate is to study its immunogenicity on its own. In addition a life vaccine candidate must also be non-pathogenic [23] . In this work we immunized BALB/c mice with mycelium of Streptomyces lividans 1326.
RESULTS AND DISCUSSION
Using ELISA analyses, it was shown that groups of mice immunized with S. lividans 1326 strain or with the BCG vaccine produced significant amount of antibodies against the secreted proteins recovered from the culture supernatant of each strain respectively (Fig. 1A) . The levels of antibodies were significant from day 21 after the first immunization for the Streptomyces immunized group and from day 42 for the BCG immunized group (i.e. 21 days after the second immunization). Maximum levels of antibodies for all the experimental groups were found at day 63 of the experiment (21 days after the third immunization). The presence of the reacting antibodies against the secreted proteins detected by ELISA in Fig. (1A) was confirmed by Western blot analyses (Fig. 1B) . Serum antibodies from Streptomyces immunized mice recognized proteins of different molecular weight present in the spent culture medium of Streptomyces and the sera from BCG immunized animals also reacted with different proteins secreted by this vaccine strain. No immunoreactivity against S. lividans 1326 or BCG was observed using sera from the PBS immunized group. Fig. (1) confirms the value of S. lividans as a potential vehicle for delivering secreted proteins in an appropriate manner for inducing a strong humoral response against these antigens. This response is highly relevant in view of the cross reaction between the secreted proteins of S. lividans and M. tuberculosis. It is known that the high affinity phosphate-binding proteins PstS from S. lividans and S. coelicolor share 42-43% of sequence identity with PstS-1, PstS-2 and PstS-3 from M. tuberculosis [24] , and that PstS-1 is one of the major immunodominant antigens of M. tuberculosis [25] .
The capacity of sera from mice immunized with Streptomyces and BCG to react with whole cells of each strain was analyzed by means of ELISA, using Streptomyces mycelium or BCG cells for coating microtiter plates (Fig. 2) . It was found that antibodies obtained from Streptomyces and BCG immunized animals were able not only to react with the secreted proteins from each strain but also with whole Streptomyces and BCG cells. Moreover antibodies from Streptomyces immunized mice recognized whole BCG cells equally well as in the reciprocal tests with BCG induced antibodies.
The results shown in Figs. (1 and 2) indicate that the Streptomyces mycelium is strongly immunogenic in the murine model and is not pathogenic at the used doses. In previous studies, Streptomyces bacteria were found to be unable to colonize organs like heart, liver, kidney, lung or spleen in intranasal, intramuscular or intraperitoneal immunized BALB/c mice as indicated by microbiological analyses, and histopathological analyses revealed no lesions in these organs [26] .
The degree of cross-reactivity observed between the proteins of the culture supernatants was the same irrespective of whether antibodies induced by Streptomyces or BCG were used (Fig. 3) . The antibody responses against M. tuberculosis secreted proteins were similar in the groups of animals immunized with the Mycobacterium bovis vaccine strain and the Streptomyces strain, indicating cross-reactivity between Streptomyces and the Mycobacterium genus. However, the antibody reactivity obtained against the M. tuberculosis secreted proteins was not as high as the antibody reactivity obtained against the secreted protein pattern of Streptomyces or BCG (Fig. 1A) . Phylogenetic proximity analysis has shown that these two species of bacteria belonging to the Actinomycete order, are closely related [27] .
Antigen-Specific Lymphocyte Proliferative Response and Cytokine Production in Splenocytes of Immunized Mice
In order to evaluate the capacity of immunization with Streptomyces mycelium to raise a cellular response, the lymphocytes isolated from the spleens of experimental animals were re-exposed to the secreted antigenic proteins. The proliferation of the lymphocyte populations from the bacteria-immunized mice (Fig. 4) was significant when challenged with secreted proteins of both Streptomyces and Beside the lymphocyte proliferation, the levels of IFN , and IL-10 secreted in vitro from the re-stimulated lymphocytes were also measured by ELISA ( Table 2 ). The immunization with S. lividans 1326 in mice was found to elicit a strong cellular immune response leading to levels of 2103.9 pg/ml of the major Th1-type cytokine IFN-, which are as high as those observed by other authors [28] . In contrast, immunization with BCG produced a lower Th1 response than with the Streptomyces strain. Similarly to the humoral response, lymphocytes from the Streptomyces immunized group, when challenged with BCG secreted antigens, secreted similar quantities of IFN-and IL-10 as the lymphocytes from BCG immunized animals.
During normal phagocytosis, the contents of the bacilluscontaining phagosome are degraded upon fusion with lysosomes, but during infection with M. tuberculosis this process is blocked [29, 30] . The inhibition of phagosome maturation by mycobacteria may be reverted by cytokines, such as IFN-and TNF- [31] ; and in this respect S. lividans seems to create a favorable response with cross-reacting proteins promoting a Th1 immune response. Since the tubercle bacilli reside inside a compartment within the macrophage, their antigens are presented by MHC class II molecules to CD4+ T lymphocytes. The main function of CD4+ T cells is the production of cytokines including IFN-, which activates macrophages and promotes bacilli destruction. Recently, another function has been ascribed to these cells, i.e., helping to develop the CD8+ T cell mediated response [32, 33] . In the same way, CD4+ T cells may participate in the induction of apoptosis of infected cells and subsequent reduction of bacterial viability through the CD95 Fas ligand system [34] . Therefore, formulations that induce the production of enduring Th1 responses are desirable and are an essential element of a successful TB vaccine.
CONCLUSION
The S. lividans strain 1326 possessed adequate immunogenicity in BALB/c mice when used under the conditions described in this paper, confirming the potential of this bacterium as a delivering system for its secreted proteins. The cellular immune response toward Streptomyces was in some cases stronger than the response obtained with BCG immunized animals, as shown by the proliferation assays and levels of IFN-secreted by leukocytes against homologous antigens. Genetic variation between BCG strains used in different trials may explain the differences in efficacy that have been reported [35] .
This first study of the murine immune response toward Streptomyces suggests that it may be worthwhile to characterize the immune response and protective efficacy of others Streptomyces strains, such as wild-type strains and recombinant strains secreting Mycobacterium tuberculosis antigens. 
